Search results for: Market Access
Filter search results
A Market-based International Reference Price Index: Solution or Contradiction?
13 September 2019
…market-based arrangements for determining drug prices [3]. This reflects Roy’s view that market mechanisms are the best way to establish prices that reflect the underlying preferences for health care of…
The US Inflation Reduction Act: What Do the Experts Think?
25 May 2023
…Part D redesign. I will not explain the provisions in detail here, but for those interested in learning more, you can access a comprehensive description in our freely accessible IRA…
Would Waiving COVID-19 Vaccines Patents Save Lives?
18 May 2021
…https://www.economist.com/leaders/2021/05/15/ten-million-reasons-to-vaccinate-the-world[Accessed 17 May 2021]. KFF, 2021. Global COVID-19 Vaccine Access: A Snapshot of Inequality. KFF. Available at: https://www.kff.org/policy-watch/global-covid-19-vaccine-access-snapshot-of-inequality/ [Accessed 17 May 2021]. Euronews, 2021. EU nations divided over lifting COVID-19…
Plan For A New EU Pharmaceutical Legislation: What Will It Mean For Pharmaceutical Innovation?
12 April 2024
…Intellectual Property. [online] Available at: https://www.efpia.eu/about-medicines/development-of-medicines/intellectual-property/ [Accessed 11 Apr. 2024]. European Medicines Agency and Sonia Ribeiro, 2018. Data exclusivity, market protection, orphan and paediatric rewards. [online] Available at: https://www.ema.europa.eu/en/documents/presentation/presentation-data-exclusivity-market-protection-orphan-and-paediatric-rewards-s-ribeiro_en.pdf [Accessed 5 Apr. 2024]. European…
Is collaboration between and across regulatory and HTA agencies the answer to access challenges?
12 November 2024
…access to transformative medicines sooner, e.g. Delivering guidance to the NHS at an unprecedented rate (nice.org.uk); benefits for developers – in the form of market access and market readiness in…
Access to Orphan Drugs in the EU
21 October 2010
…in The Netherlands). Countries also vary with respect to pre-market access and requirements for post-launch studies. Decisions based on HTA can affect P&R and, as a result, access to OMPs by patients. …
Key Considerations for Early Access Schemes for Single-Administration (One-Time) Therapies
1 June 2021
…an early access scheme: therapies that qualify for early access should become available through early access schemes as soon as it is deemed safe to do so. Access to therapies…
Can Transparency Lower Prices and Improve Access to Pharmaceuticals? Five Questions We Think Matter a Lot
29 March 2019
…Figure below, two-thirds of the market by value in low and lower middle-income markets included in CGD’s analysis goes to, almost exclusively, branded generics. Further review of data from a…
Rare Disease Day 2024: Why Do We Care About Rare?
29 February 2024
…Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries – OHE. Office of Health Economics. Published January 3, 2017. Accessed February 27, 2024. https://www.ohe.org/publications/comparing-access-orphan-medicinal-products-omps-united-kingdom-and-other-european/ Garau…